SEC Form 4 · accession 0000899243-17-010274
SOLENO THERAPEUTICS INC · SLNO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Rajen Dalal
Director
Period of report
Apr 7, 2017
Accepted (ET)
Apr 13, 2017 · 8:58 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001484565
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jan 23, 2017 | A | 7,315 | $0.90 | A | 7,315 | D | |
| Common StockF1,F3 | Apr 7, 2017 | A | 10,450 | $0.63 | A | 17,765 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Effective January 1, 2017, annual board and committee retainers payable to directors will be made in equivalent shares of the Issuer's common stock, on a quarterly basis.
- F2The number of shares issuable in lieu of cash retainers was determined using the closing price per share of Issuer common stock on January 23, 2017, or $0.90.
- F3The number of shares issuable in lieu of cash retainers was determined using the closing price per share of Issuer common stock on April 7, 2017, or $0.63.